Pharmacodynamic breakpoints for ciprofloxacin efficacy and resistance in critically ill patients treated with continuous venovenous hemodialysis: a prospective case series study.
Completed
- Conditions
- Bacterial infectionRenal Insufficiency1000401810038430
- Registration Number
- NL-OMON41806
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
• Admission to the ICU of the Zaandam Medical Center during the study period
• Expected to be undergoing CVVHD for >24 h
• Treatment with ciprofloxacin for any infection or suspected infection, as judged by the attending physician.
• Age >= 18 years
Exclusion Criteria
• Cessation of renal replacement therapy before obtainment of a through sample
• No CRRT delivered during >25 % of the interval between obtainment of peak and through plasma samples.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint in our study is the theoretical pharmacodynamic breakpoint<br /><br>for efficacy, calculated by means of the following formula:<br /><br><br /><br>TP BPeff = AUC24-ss / 125 (where AUC24-ss is the estimated AUC at steady state<br /><br>during a 12 h dosing interval multiplied by 2)</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary endpoint in our study is the theoretical pharmacodynamic<br /><br>breakpoint for the emergence of resistance, calculated by means of the<br /><br>following formula:<br /><br><br /><br>TP BPres = Cmax-ss / 10 (where Cmax-ss is the estimated plasma concentration<br /><br>30 minutes after ending a ciprofloxacin infusion at steady state)</p><br>